Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation

Clinical Chemistry

Volumn 52, Issue 8, 2006, Pages 1568-1574

  Kort, Sheila A R ^a   Martens, Frans ^a   Vanpoucke, Hilde ^b   Van Duijnhoven, Hans L ^c   Blankenstein, Marinus A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Heilig Hart Ziekenhuis   (Belgium)

^c ELKERLIEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOASSAY; BLOOD LEVEL; BLOOD SAMPLING; CALCULATION; COMPLEXED PROSTATE SPECIFIC ANTIGEN; CONFIDENCE INTERVAL; DIAGNOSTIC KIT; FREE PROSTATE SPECIFIC ANTIGEN; FREE PROSTATE SPECIFIC ANTIGEN TOTAL PROSTATE SPECIFIC ANTIGEN RATIO; HUMAN; INTERMETHOD COMPARISON; LABORATORY AUTOMATION; MATHEMATICAL ANALYSIS; STANDARD; TOTAL PROSTATE SPECIFIC ANTIGEN; WORLD HEALTH ORGANIZATION;

AUTOANALYSIS; CHYMOTRYPSIN; HUMANS; IMMUNOASSAY; LINEAR MODELS; PROSTATE-SPECIFIC ANTIGEN; PROTEIN BINDING; REFERENCE STANDARDS; REGRESSION ANALYSIS; WORLD HEALTH ORGANIZATION;

EID: 33746633333     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.069039     Document Type: Article

References (19)

1. Auvinen A, Rietbergen JB, Denis LJ, Schröder FH, Prorok PC. Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996;3:97-104.
2. Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005;97:433-8.
3. Armbruster DA. Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 1993;39:181-95.
4. Patel D, White PA, Milford Ward A. A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA. BJU Int 2000;85: 686-9.
5. Ward AM, Catto JW, Hamdy FC. Prostate specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem 2001;38:633-51.
6. Gion M, Mione R, Barioli P, Barichello M, Zattoni F, Prayer-Galetti T, et al. Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions. Clin Chem 1998;44:2462-70.
7. Gann PH, Ma J, Catalona WJ, Stampfer MJ. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol 2002;167: 2427-34.
8. Tanguay S, Begin LR, Elhilali MM, Behlouli H, Karakiewicz PI, Aprikian AG. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 2002; 59:261-5.
9. Tewari PC, Williams JS. Analytical characteristics of seminal fluid PSA differ from those of serum PSA. Clin Chem 1998;44:191-3.
10. Blase AB, Sokoloff RL, Smith KM. Five PSA methods compared by assaying samples with defined PSA ratios. Clin Chem 1997;43: 843-5.
11. Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006;52:59-64.
12. Rafferty B, Rigsby P, Rose M, Stamey T, Gaines Das R. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin Chem 2000;46:1310-7.
13. Stamey TA, Chen Z, Prestigiacomo AF. Reference material for PSA: the IFCC standardization study. International Federation of Clinical Chemistry. Clin Biochem 1998;31:475-81.
14. Roddam AW, Rimmer J, Nickerson C, Ward AM. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem 2006;43:35-48.
15. Ishibashi M. Standardization of prostate-specific antigen (PSA) assays: can interchangeability of PSA measurements be improved? Clin Chem 2006;52:1-2.
16. Semjonow A, De Angelis G, Oberpenning F, Schmid HP, Brandt B, Hertle L. The clinical impact of different assays for prostate specific antigen. BJU Int 2000;86:590-7.
17. Van Duijnhoven HL, Peq́uériaux NC, Van Zon JP, Blankenstein MA. Large discrepancy between prostate-specific antigen results from different assays during longitudinal follow-up of a prostate cancer patient. Clin Chem 1996;42:637-41.
18. Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH, Wildhagen MF, Schroder FH. Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU Int 2001;88:545-50.
19. Chan DW, Sokoll U. WHO first international standards for prostate-specific antigen: the beginning of the end for assay discrepancies? Clin Chem 2000;46:1291-2.